As Sanguine increases its presence on the biomarker development front, the company’s clients will demand bioassay development services, and TGA is now well positioned to receive a larger volume of requests for biomarker development services, the company claimed.
Sanguine Biospecimen Marketing Vice President David Winternheimer said the deal with TGA would help them provide additional services from a CRO with experience in cell-based bioassays.
"We are excited to enter into this co-marketing agreement with Sanguine, and are hopeful it will help us expand our client base in Europe as well as help us increase the scope of our bioassay services," Winternheimer added.